KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Dosing to Effect With Weekly and Monthly Subcutaneous and Daily Sublingual Buprenorphine: Post Hoc Analysis of a Phase 3 Clinical Trial.

Michelle R Lofwall, Edward V Nunes, Sharon L Walsh, Genie L Bailey, Michael Frost, Natalie R Budilovsky-Kelley, Elin Banke Nordbeck, Susanna Meyner, Peter Almgren, Stefan Peterson, Fredrik Tiberg

J Addict Med 19(6) 676-684

PMID40193234
PMCIDPMC12577654
DOI10.1097/ADM.0000000000001484
发表日期2025-04-07
入排依据:未发现恶性肿瘤人群证据。
已检查 5 张 PubMed Figure,均未识别为 KM 图:FIGURE 1:AI 判定为 flow diagram;FIGURE 2:AI 判定为 other;FIGURE 3:AI 判定为 other;FIGURE 4:AI 判定为 other;FIGURE 5:AI 判定为 other。
摘要

摘要

OBJECTIVES: CAM2038 weekly and monthly extended-release buprenorphine (BPN) formulations are effective for treating opioid use disorder (OUD). Little is known about the effect of dose on patient outcomes, particularly under blinded and flexible dosing conditions. We evaluated the number of dose changes and the impact of (1) dose on treatment outcomes and (2) baseline primary opioid use (heroin vs prescription opioids) and route of use (injection or not) on the dose. METHODS: This was a post hoc analysis of an outpatient randomized double-blind, double-dummy trial comparing weekly (first 12 wk) and monthly (second 12 wk) CAM2038 to SL-BPN (24 wk) for OUD treatment. Dosing was flexible and guided by clinical response. Maximum doses were 32 mg weekly/160 mg monthly CAM2038 and 24 mg/32 mg SL-BPN in the first and second 12 weeks, respectively. Effect of each dose was evaluated using four outcomes: urine drug test (UDT) opioid results, Clinical Opiate Withdrawal Scale scores, Subjective Opiate Withdrawal Scale scores, and need- and desire-to-use opioid visual analogue scales. Associations between baseline route of use and primary opioid used and study dose were investigated. RESULTS: After titration to 16 mg SL-BPN/24 mg weekly CAM2038, most participants had 0-1 dose adjustments in both first and second 12 weeks. All doses were utilized. Number of adjustments was not associated with retention. Withdrawal, craving, and opioid-positive UDTs decreased for all CAM2038 and SL-BPN doses. There were few clinically significant associations between dose and primary opioid used/route of use. CONCLUSIONS: Results support current practice guidelines, emphasizing the importance of individualized dosing based on patient response.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(5,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIGURE 1FIGURE 1 Trial design. There was a 1-month follow-up after phase 2. Adapted from Lofwall et al. BL indicates baseline; BPN, buprenorphine; SC, subcutaneous; SL, sublingual; SL-BPN, sublingual buprenorphine.
非 KM Figure
FIGURE 2FIGURE 2 Number of dose changes. Bars show number of dose changes between: (A–B) day 1 week 4 in participants who had a week 12 visit whereby the protocol required one dose increase in the first week; (C–D) weeks 5–12 in participants who had a week 12 visit; and (E–F) weeks 13–21 in participants who had a week 21 visit. SL-BPN indicates sublingual buprenorphine.
非 KM Figure
FIGURE 3FIGURE 3 Doses administered to participants at week 12 and week 21 of the trial, stratified by primary opioid use reported at initiation (A–D) and whether participants reported a history of injection opioid use (E–H). Data represent the dose that a participant received at their week 12 (A–B and E–F) and week 21 (C–D and G–H) visits, stratified by the primary opioid being used at study initiation (A–D), and by whether participants reported a history of injection opioid use (E–H). P values represent nominal P values from the Fisher exact test. SL-BPN indicates sublingual buprenorphine.
非 KM Figure
FIGURE 4FIGURE 4 Percentage of urine samples negative for opioids. Data represent the mean percentage of negative opioid UDT tests from weeks 5–24 of the trial (excluding the 4-week initial dose titration period at the beginning of the trial). As participants’ doses could have been adjusted over time, the same participant may be present at different times in the different dose categories within the assigned group. Numbers below the x -axis label represent the number of participants making up each dose category. SL-BPN indicates sublingual buprenorphine; UDT, urine drug test.
非 KM Figure
FIGURE 5FIGURE 5 Opioid withdrawal and craving scores. Data represent mean COWS, SOWS, need-to-use VAS, and desire-to-use VAS scores recorded for participants the visit after they received the specified dose, from weeks 5-24 of the trial (excluding the 4-week initial dose titration period at the beginning of the trial). BL indicates baseline; COWS, Clinical Opiate Withdrawal Scale; SL-BPN, sublingual buprenorphine; SOWS, Subjective Opiate Withdrawal Scale; VAS, visual analog scale.
非 KM Figure